Diversity and Equity Are Critical to the Work We Do
Systemic racism is as real as any disease.
The biopharmaceutical industry is committed to driving real change and improving health outcomes for patients in underserved communities.
Our Commitment to Equity
Equity is critical to the health and well-being of Black and Brown communities, and it remains essential to a robust ecosystem of innovation. America’s biopharmaceutical companies are pushing for necessary systemic and long-term change to better meet the needs of Black and Brown America.
Our Continued Commitment to Industry Change
Health Equity
We’re working with patients, community groups and policymakers to address
social determinants of health and to drive proactive research that expands
data collection and improves health outcomes.
We’re committed to working toward a clinical trials infrastructure that addresses health disparities and closes the gap in clinical trial diversity to better reflect the intended treatment population.
Mobile CTA: (shows in EE only)
Talent
We aim to grow the talent pool, create new pathways to our industry and foster more inclusive work environments so that our workforce better reflects census representation top to bottom and side to side.
Voices from Our Catalyst Blog
Systemic racism is as real as
any disease and our industry
is not immune
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA will continue to
advocate for equity within our
industry
Three ways the pharmaceutical industry can positively impact health equity
Systemic racism is as real as
any disease and our industry
is not immune
Systemic racism is as real as
any disease and our industry
is not immune
PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in DC-based, Black-owned newspapers the Informer and the AfroAmerican. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future…
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
Strengthening a culture dedicated to patients and equity: A conversation with Vas Narasimhan, CEO of Novartis
This year our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. Outside of the novel coronavirus, major social issues have been brought to the forefront of public discourse. We understand that systematic racism is as real as any disease and...
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view.
PhRMA will continue to
advocate for equity within our
industry
PhRMA will continue to
advocate for equity within our
industry
When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior director of talent acquisition, some of my first tasks were to build an inhouse recruiting team and develop a D&I strategy for the organization…
Three ways the pharmaceutical industry can positively impact health equity
Three ways the pharmaceutical industry can positively impact health equity
“Creating a trusted partnership between the biopharmaceutical industry and communities of color will not happen overnight. It will take a sustained commitment to establish meaningful relationships that move us from health disparity to health equity.
I urge you to follow the progress at PhRMA.org/Equity.”
Reports and Agency Comments
Medicines in Development for Health Equity 2021 Report
Today, more than 1,300 medicines and vaccines for various cancers are currently in development by innovative biopharmaceutical research companies, all of which are in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA).
